Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
U.S. Treasury Eyes Private Credit Oversight Through Insurance Regulator Talks 
Dollar Surges to Nine-Month High as Middle East Tensions Drive Safe-Haven Demand 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Gold Prices Inch Higher Amid U.S.-Iran War Tensions and Technical Rebound 
U.S. Jobs Market Eyes March Recovery Amid Inflation Pressures 
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Iran Strikes Oil Tanker Near Dubai Amid U.S. Threats and Ongoing Middle East Conflict 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Oil Prices Dip as Trump Eyes Iran De-escalation, Hormuz Closure Persists 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
WTO Digital Trade Talks Stall as E-Commerce Tariff Deadline Looms 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
